1. Doudna, J. A. The promise and challenge of therapeutic genome  editing. Nature. 2020, 578, 229-236. 2. Gillmore, J. D.; Gane, E.; Taubel, J.; Kao, J.; Fontana, M.; Maitland, M.  L.; Seitzer, J.; O’Connell, D.; Walsh, K. R.; Wood, K.; Phillips, J.; Xu,  Y.; Amaral, A.; Boyd, A. P.; Cehelsky, J. E.; McKee, M. D.; Schiermeier,  A.; Harari, O.; Murphy, A.; Kyratsous, C. A.; Zambrowicz, B.; Soltys,  R.; Gutstein, D. E.; Leonard, J.; Sepp-Lorenzino, L.; Lebwohl, D.  CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis. N Engl  J Med. 2021, 385, 493-502. 3. van Haasteren, J.; Li, J.; Scheideler, O. J.; Murthy, N.; Schaffer, D. V.  The delivery challenge: fulfilling the promise of therapeutic genome  editing. Nat Biotechnol. 2020, 38, 845-855. 4. Xu, X.; Wan, T.; Xin, H.; Li, D.; Pan, H.; Wu, J.; Ping, Y. Delivery of  CRISPR/Cas9 for therapeutic genome editing. J Gene Med. 2019, 21,  e3107. 5. Behr, M.; Zhou, J.; Xu, B.; Zhang, H. In vivo delivery of CRISPR-Cas9  therapeutics: progress and challenges. Acta Pharm Sin B. 2021, 11, 2150- 2171. 6. Wan, T.; Zhong, J.; Pan, Q.; Zhou, T.; Ping, Y.; Liu, X. Exosomemediated delivery of Cas9 ribonucleoprotein complexes for tissuespecific gene therapy of liver diseases. Sci Adv. 2022, 8, eabp9435. 7. Kalluri, R.; LeBleu, V. S. The biology, function, and biomedical  applications of exosomes. Science. 2020, 367, eaau6977. 8. Horodecka, K.; Düchler, M. CRISPR/Cas9: principle, applications, and  delivery through extracellular vesicles. Int J Mol Sci. 2021, 22, 6072. 9. Fang, R. H.; Kroll, A. V.; Gao, W.; Zhang, L. Cell membrane coating  nanotechnology. Adv Mater. 2018, 30, e1706759. 10. Guo, H.; Zhang, W.; Wang, L.; Shao, Z.; Huang, X. Biomimetic  cell membrane-coated glucose/oxygen-exhausting nanoreactor for  remodeling tumor microenvironment in targeted hypoxic tumor  therapy. Biomaterials. 2022, 290, 121821.